It would seem to be counterintuitive that any cancer cell line progression series would activate a strong antiangiogenic program, and indeed, we can find in our invasive transcriptomic profile at least two established angiogenic activators—Angiopoietin-2 [94] and c-fos–induced growth factor coding for vascular endothelial growth factor D [95]. The gene discussed is FOS; the disease is cancer.